Evidence map›Paper›PMID 37303136›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2023

Toward Integration of Pharmacogenomic Tests into Daily Clinical Practice: A General Survey for Polish Healthcare Workers.

Alireza Tafazoli, Agnieszka Kitlas Golińska, Krzysztof Mnich, Alireza Amirabadizadeh, Jennifer Clark Marquez, Wojciech Miltyk

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Alireza TafazoliDepartment of Analysis and Bioanalysis of Medicines, Faculty of Pharmacy with The Division of Laboratory Medicine, Białystok, Poland.ORCID 0000-0002-0344-9941
Agnieszka Kitlas GolińskaInstitute of Computer Science, University of Białystok, Białystok, Poland.
Krzysztof MnichComputational Center, University of Białystok, Białystok, Poland.
Alireza AmirabadizadehEndocrine Research Center, Research Institute for Endocrine Sciences, Beheshti University of Medical Sciences, Tehran, Iran.
Jennifer Clark MarquezJohn B. Amos Cancer Center, Columbus, GA, USA.
Wojciech MiltykDepartment of Analysis and Bioanalysis of Medicines, Faculty of Pharmacy with The Division of Laboratory Medicine, Białystok, Poland.
Medical University of Białystok · PLUniversity of Białystok · PLResearch Institute for Endocrine Sciences · IRSaint John's Health Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Pharmacogenomics (PGx) has a direct influence on personalized drug therapy for various types of disorders and has been proven to have an important role in the future of medicine. The present study evaluated the awareness of PGx testing of clinicians and healthcare workers in the Republic of Poland. To the best of our knowledge, this is the first direct assessment of Polish healthcare professionals' attitudes toward introducing PGx tests into daily clinical practice. MATERIAL AND METHODS We used a comprehensive anonymous questionnaire with queries on level of education, background knowledge of PGx tests, advantages and barriers for implementation of such tests, and clinicians' desire to order the test that was distributed online to doctors, healthcare workers, related students/Ph.D. students, and administrative staff managing healthcare units. RESULTS We gathered 315 responses. According to the answers, two-thirds of participants had heard about PGx before (64.4%). An overwhelming majority of respondents appreciated the benefits of PGx (93.3%). Indeed, prior knowledge and level of education showed significant associations with positive attitudes toward PGx clinical testing (P≤0.05). However, all participants agreed there are major challenges for including such tests as part of routine clinical practice. CONCLUSIONS While the awareness and interest in PGx clinical testing in Polish healthcare providers are rising, some main barriers for implementation of these tests still need to be addressed in Poland.

Indexed as

PharmacogeneticsPhysiciansEducational StatusHealth PersonnelHumansPoland

Identifiers

PMID37303136
PMCPMC10274214
OpenAlexW4368363693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.